Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(2): 341-348
CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei. Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139
Citation: CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei. Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139
shu

Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma

doi: 10.12290/xhyxzz.2021-0139

  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: BAI Chunmei, E-mail: baichunmei1964@163.com
  • Received Date: 2021-02-01
  • Accepted Date: 2021-02-26
  • Publish Date: 2022-03-30
    Abstract
  • Due to the immunosuppressive microenvironment as well as the lack of medicine that targets the driver gene alterations, the prognosis of patients with pancreatic ductal adenocarcinoma(PDAC)is worse than that of other malignant tumors.At present, chemotherapy is still the main stay of treatment for most patients with advanced PDAC. In recent years, with the continuous development of anti-cancer drugs and the wide application of next-generation sequencing technology, increasing number of studies have shown that genetic alteration could guide the selection of chemotherapy regimen and molecular targeted therapy for some patients with advanced PDAC.Guidelines of the National Comprehensive Cancer Network and Chinese Society of Clinical Oncology recommend that all patients with advanced PDAC should undergo somatic and germline genetic profiling to help determining the optimal treatment strategy and to prolong patients' survival. Therapy targeting KRAS mutation, cancer vaccines and therapy of anti-tumor metabolism are still in clinical research. This article will review current status and progress of medical treatment for advanced PDAC.
    • FullText(HTML)
  • loading
    • References(58)
  • [1] American Cancer Society. Facts & Figures 2014[EB/OL]. [2021-02-20]. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html.
    [2] American Cancer Society. Facts & Figures 2020[EB/OL]. [2021-12-20]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf.
    [3] Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020, 21: e342-e349. doi:  10.1016/S1470-2045(20)30073-5
    [4] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6: e555-e567. doi:  10.1016/S2214-109X(18)30127-X
    [5] SEER Cancer Stat Facts: Pancreatic Cancer[EB/OL]. (2021-04-15)[2021-12-20]. https://seer.cancer.gov/statfacts/html/pancreas.html.
    [6] O'Reilly EM, Surinach A, Wu Z, et al. Real-world patterns of care among patients with metastatic pancreatic cancer (mPC)[J]. J Clin Oncol, 2020, 38: 666.
    [7] Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15: 2403-2413. doi:  10.1200/JCO.1997.15.6.2403
    [8] Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31: 1640-1648. doi:  10.1200/JCO.2012.43.3680
    [9] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364: 1817-1825. doi:  10.1056/NEJMoa1011923
    [10] Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369: 1691-1703. doi:  10.1056/NEJMoa1304369
    [11] Kang J, Hwang I, Yoo C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis[J]. Invest New Drugs, 2018, 36: 732-741. doi:  10.1007/s10637-018-0598-5
    [12] Nakazawa J, Otsuka T, Shimokawa M, et al. A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study[J]. Ann Oncol, 2019, 30: iv17-iv18.
    [13] Pusceddu S, Ghidini M, Torchio M, et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis[J]. Cancers (Basel), 2019, 11: 484. doi:  10.3390/cancers11040484
    [14] Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation[J]. Br J Cancer, 2020, 122: 333-339. doi:  10.1038/s41416-019-0582-7
    [15] Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers[J]. Br J Cancer, 2014, 111: 1132-1138. doi:  10.1038/bjc.2014.418
    [16] O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase Ⅱ Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation[J]. J Clin Oncol, 2020, 38: 1378-1388. doi:  10.1200/JCO.19.02931
    [17] Pishvaian MJ, Blais EM, Brody JR, et al. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program[J]. JCO Precis Oncol, 2019, 3: 1-10.
    [18] Park W, Chen J, Chou JF, et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection[J]. Clin Cancer Res, 2020, 26: 3239-3247. doi:  10.1158/1078-0432.CCR-20-0418
    [19] National Comprehensive Cancer Network®(NCCN®). Pancreatic Adenocarcinoma. Version 2.2021[EB/OL]. (2021-02-25)[2021-12-20]. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
    [20] 中国临床肿瘤学会. 胰腺癌诊疗指南2020[EB/OL ]. (2020-11-09)[2021-12-20]. http://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/202011/2020119641817.pdf.

    Chinese Society of Clinical Oncology(CSCO). Guidelines of pancreatic cancer 2020[EB/OL ]. (2020-11-09)[2021-12-20]. http://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/202011/2020119641817.pdf.
    [21] Casolino R, Paiella S, Azzolina D, et al. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis[J]. J Clin Oncol, 2021, 39: 2617-2631. doi:  10.1200/JCO.20.03238
    [22] Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 387: 545-557. doi:  10.1016/S0140-6736(15)00986-1
    [23] Oettle H, Riess H, Stieler JM, et al. Second-line oxalipla-tin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial[J]. J Clin Oncol, 2014, 32: 2423-2429. doi:  10.1200/JCO.2013.53.6995
    [24] Gill S, Ko YJ, Cripps C, et al. PANCREOX: A Randomized Phase Ⅲ Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy[J]. J Clin Oncol, 2016, 34: 3914-3920. doi:  10.1200/JCO.2016.68.5776
    [25] Sawada M, Kasuga A, Mie T, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer[J]. BMC Cancer, 2020, 20: 449. doi:  10.1186/s12885-020-06945-8
    [26] Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort[J]. Br J Cancer, 2015, 113: 989-995. doi:  10.1038/bjc.2015.328
    [27] Mita N, Iwashita T, Uemura S, et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure[J]. J Clin Med, 2019, 8: 761. doi:  10.3390/jcm8060761
    [28] Baron MK, Wang X, Nevala-Plagemann C, et al. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma[J]. Pancreas, 2021, 50: 796-802. doi:  10.1097/MPA.0000000000001844
    [29] Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25: 1960-1966. doi:  10.1200/JCO.2006.07.9525
    [30] Dreyer SB, Chang DK, Bailey P, et al. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development[J]. Clin Cancer Res, 2017, 23: 1638-1646. doi:  10.1158/1078-0432.CCR-16-2411
    [31] Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovar-ian Cancer[J]. N Engl J Med, 2018, 379: 2495-2505. doi:  10.1056/NEJMoa1810858
    [32] Reiss KA, Mick R, O'Hara MH, et al. Phase Ⅱ Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2[J]. J Clin Oncol, 2021, 39: 2497-2505. doi:  10.1200/JCO.21.00003
    [33] Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28: 2429-2435. doi:  10.1093/annonc/mdx343
    [34] Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors[J]. N Engl J Med, 2020, 383: 1207-1217. doi:  10.1056/NEJMoa1917239
    [35] Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients[J]. Cancer Discov, 2020, 10: 54-71. doi:  10.1158/2159-8290.CD-19-1167
    [36] Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor[J]. J Med Chem, 2021. doi:  10.1021/acs.jmedchem.1c01688.
    [37] AACR-NCI-EORTC virtual international conference on molecular targets and cancer therapeutics. Discovery and Development of RAS(ON) Inhibitors Beyond KRASG12C[EB/OL ]. (2021-10-09)[2021-12-20]. https://ir.revmed.com/static-files/ad588f56-5608-4ad6-9816-be40b38eb974.
    [38] Kato S, Adashek JJ, Shaya J, et al. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics[J]. Clin Cancer Res, 2021, 27: 2792-2797. doi:  10.1158/1078-0432.CCR-20-3761
    [39] Jones MR, Williamson LM, Topham JT, et al. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2019, 25: 4674-4681.
    [40] Heining C, Horak P, Uhrig S, et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer[J]. Cancer Discov, 2018, 8: 1087-1095. doi:  10.1158/2159-8290.CD-18-0036
    [41] Pishvaian MJ, Rolfo CD, Liu SV, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions[J]. J Clin Oncol, 2018, 36: 521.
    [42] O'Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion[J]. Ann Oncol, 2019, 30: viii36-viii40. doi:  10.1093/annonc/mdz385
    [43] Singhi AD, Ali SM, Lacy J, et al. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma[J]. J Natl Compr Canc Netw, 2017, 15: 555-562. doi:  10.6004/jnccn.2017.0058
    [44] Gower A, Golestany B, Gong J, et al. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib[J]. JCO Precis Oncol, 2020, 4: PO. 19.00365.
    [45] Guan M, Bender RJ, Pishvaian MJ, et al. Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs)[J]. J Clin Oncol, 2018, 36: 214.
    [46] Li H-S, Yang K, Wang Y. Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report[J]. Gastroenterol Rep, 2021: goab031. doi:  10.1093/gastro/goab031.
    [47] Schram AM, O'Reilly EM, O'Kane GM, et al. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions[J]. J Clin Oncol, 2021, 39: 3003. doi:  10.1200/JCO.2021.39.15_suppl.3003
    [48] Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500: 415-421. doi:  10.1038/nature12477
    [49] O'Reilly EM, Oh DY, Dhani N, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancre-atic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5: 1431-1438. doi:  10.1001/jamaoncol.2019.1588
    [50] Renouf DJ, Knox JJ, Kavan P, et al. LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase Ⅱ study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)[J]. Ann Oncol, 2020, 31: S1195. doi:  10.1016/j.annonc.2020.08.2300
    [51] Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial[J]. Nat Med, 2020, 26: 878-885. doi:  10.1038/s41591-020-0880-x
    [52] O'Hara MH, O'Reilly EM, Wolff RA, et al. Gemcitabine (Gem) and nab-paclitaxel (NP) ±nivolumab (nivo) ±CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results[J]. J Clin Oncol, 2021, 39: 4019. doi:  10.1200/JCO.2021.39.15_suppl.4019
    [53] Le DT, Picozzi VJ, Ko AH, et al. Results from a Phase Ⅱb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)[J]. Clin Cancer Res, 2019, 25: 5493-5502. doi:  10.1158/1078-0432.CCR-18-2992
    [54] Tsujikawa T, Crocenzi T, Durham JN, et al. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer[J]. Clin Cancer Res, 2020, 26: 3578-3588. doi:  10.1158/1078-0432.CCR-19-3978
    [55] Wu AA, Bever KM, Ho WJ, et al. A Phase Ⅱ Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer[J]. Clin Cancer Res, 2020, 26: 5129-5139. doi:  10.1158/1078-0432.CCR-20-1025
    [56] Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients[J]. Oncotarget, 2015, 6: 24560-24570. doi:  10.18632/oncotarget.4183
    [57] Alistar A, Morris BB, Desnoyer R, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial[J]. Lancet Oncol, 2017, 18: 770-778. doi:  10.1016/S1470-2045(17)30314-5
    [58] Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial[J]. Lancet Oncol, 2020, 21: 508-518. doi:  10.1016/S1470-2045(20)30074-7
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (433) PDF downloads(55) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return